ReviewCurrent opinion in virology2014
Antiviral drugs specific for coronaviruses in preclinical development.
Review in Current opinion in virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04420260 (Scheme of Primary Prevention of Infection by COVID-19, in Workers), which is not on this map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Scheme of Primary Prevention of Infection by COVID-19, in Workers: Phase II Controlled Clinical Trial, to be Carried Out in Medellín-Antioquia
Who cites it
56 citing papers in PubMed.
- FDA-approved drugs as potential covalent inhibitors of key SARS-CoV-2 proteins: an in silico approach.Turkish journal of biology = Turk biyoloji dergisi · 2025Article
- Development of Fluorescence-Based Assays for Key Viral Proteins in the SARS-CoV-2 Infection Process and Lifecycle.International journal of molecular sciences · 2024Review
- Ayurvedic and Chinese Herbs against Coronaviruses.Current pharmaceutical design · 2024Review
- Discovery of Novel Cysteine Protease Inhibitors for the Treatment of Coronavirus (COVID-19).Current medicinal chemistry · 2024Article
- Free energy perturbation-based large-scale virtual screening for effective drug discovery against COVID-19.The international journal of high performance computing applications · 2023Article
- In Silico Approach for the Evaluation of the Potential Antiviral Activity of Extra Virgin Olive Oil (EVOO) Bioactive Constituents Oleuropein and Oleocanthal on Spike Therapeutic Drug Target of SARS-CoV-2.Molecules (Basel, Switzerland) · 2022Article
- Targeting COVID-19 pandemic: in silico evaluation of 2-hydroxy-1, 2-diphenylethanone N(4)-methyl-N(4)-phenylthiosemicarbazone as a potential inhibitor of SARS-CoV-2.Structural chemistry · 2022Article
- Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay.Communications biology · 2022Article
- SARS-CoV-2 Nucleocapsid Protein Has DNA-Melting and Strand-Annealing Activities With Different Properties From SARS-CoV-2 Nsp13.Frontiers in microbiology · 2022Article
- Isatin derivatives as broad-spectrum antiviral agents: the current landscape.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2022Review
- SARS-CoV-2 Antiviral Therapy.Clinical microbiology reviews · 2021Review
- Article
- Time to 'Mind the Gap' in novel small molecule drug discovery for direct-acting antivirals for SARS-CoV-2.Current opinion in virology · 2021Review
- Iterated Virtual Screening-Assisted Antiviral and Enzyme Inhibition Assays Reveal the Discovery of Novel Promising Anti-SARS-CoV-2 with Dual Activity.International journal of molecular sciences · 2021Article
- Hydroxychloroquine in COVID-19: therapeutic promises, current status, and environmental implications.Environmental science and pollution research international · 2021Review
- COVID-19 Pathogenesis: From Molecular Pathway to Vaccine Administration.Biomedicines · 2021Review
- Discovery of G-quadruplex-forming sequences in SARS-CoV-2.Briefings in bioinformatics · 2021Article
- The inhibitory effect of a coronavirus spike protein fragment with ACE2.Biophysical journal · 2021Article
- The potential effects of clinical antidiabetic agents on SARS-CoV-2.Journal of diabetes · 2021Article
- FDA recommended potent drugs against COVID-19: Insight through molecular docking.Materials today. Proceedings · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Coronaviruses are positive stranded RNA viruses that cause respiratory, enteric and central nervous system diseases in many species, including humans. Until recently, the relatively low burden of disease in humans caused by few of these viruses impeded the development of coronavirus specific therapeutics. However, the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV), and more recently, Middle East respiratory syndrome coronavirus (MERS-CoV), has impelled the development of such drugs. This review focuses on some newly identified SARS-CoV inhibitors, with known mechanisms of action and their potential to inhibit the novel MERS-CoV. The clinical development of optimized versions of such compounds could be beneficial for the treatment and control of SARS-CoV, the current MERS-CoV and other future SARS-like epidemics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.